Interestingly, it was noted that the inhibition of PAK1 also made NRAS-mutant cells more sensitive to the inhibitors of the MAPK cascade [108], suggesting an avenue to sensitize to targeted therapy this otherwise relatively resistant tumor variant. The gene discussed is PAK1; the disease is neoplasm.